Literature DB >> 1671100

Spinal kappa receptor-mediated analgesia of E-2078, a systemically active dynorphin analog, in mice.

T Nakazawa1, Y Furuya, T Kaneko, K Yamatsu.   

Abstract

E-2078 ([N-methyl-Tyr1, N-methyl-Arg7, D-Leu8]dynorphin A (1-8) ethylamide) is a systematically active dynorphin analog. We examined the sites of action of analgesia induced by systemic application of E-2078 compared with morphine in mice. When administered either intracerebroventricularly or intrathecally, E-2078 produced maximal dose-dependent analgesia in the tail-pinch, tail-flick and formalin tests. Its peak effect was observed 15 min after both injections, contrasted with a slow peak (120 min) by subcutaneous injection. The intrathecal site was relatively more sensitive than the intracerebroventricular site and many times more sensitive than the subcutaneous route. In contrast, morphine was equipotent when given intracerebroventricularly and intrathecally. When E-2078 was administered subcutaneously and naloxone or nor-binaltorphine were given either intracerebroventricularly or intrathecally, the analgesic action of E-2078 was most potently and totally reversed by intrathecal injection of nor-binaltorphimine. Intracerebroventricular and intrathecal injections of naloxone were equally effective for antagonism of morphine-analgesia. These data indicate that systemically administered E-2078 produces analgesia via central actions, in which the activation of the spinal kappa receptors is most important.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671100

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Attenuation of cannabinoid-induced inhibition of medullary dorsal horn neurons by a kappa-opioid receptor antagonist.

Authors:  Akiko Okada-Ogawa; Masayuki Kurose; Ian D Meng
Journal:  Brain Res       Date:  2010-08-31       Impact factor: 3.252

4.  Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance.

Authors:  Mei Xu; Michael Petraschka; Jay P McLaughlin; Ruth E Westenbroek; Marc G Caron; Robert J Lefkowitz; Traci A Czyzyk; John E Pintar; Gregory W Terman; Charles Chavkin
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

Review 5.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

6.  Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase.

Authors:  Mei Xu; Michael R Bruchas; Danielle L Ippolito; Louis Gendron; Charles Chavkin
Journal:  J Neurosci       Date:  2007-03-07       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.